Conformation Specific Antibodies and Diagnosis of Prion Diseases


Authors: E. Dvořáková;  K. Holada
Authors‘ workplace: Ústav imunologie a mikrobiologie, 1. LF UK a VFN v Praze
Published in: Cesk Slov Neurol N 2012; 75/108(3): 283-290
Category: Review Article

Overview

Transmissible spongiform encephalopathies, or prion diseases, are fatal neurodegenerative disorders with long incubation period and short clinical phase. The diagnosis is usually confirmed from post mortem detection of prions in the brain tissue. Most diagnostic methods are based on treatment with Proteinase K that cleaves out physiological proteins and makes the resistant form of pathological prion protein detectable with anti-prion antibodies. Over the last five years, there is a growing evidence of prionopathies caused by protease-sensitive prions escaping detection with the standard diagnostic methods. Conformation-specific monoclonal antibodies to the pathological prion proteins could overcome the problem simply by detecting the pathological conformation of both prion isoforms without the need for proteolysis. Our review summarizes available information on conformation-specific prion antibodies and discusses their use in the diagnosis of prion diseases.

Key words:
transmissible spongiform encephalopathy – prion protein – conformation-specific antibodies – Creutzfeldt-Jakob disease


Sources

1. Prusiner SB. Prions. Proc Natl Acad Sci U S A 1998; 95(23): 13363–13383.

2. Creutzfeldt HG. Über eine eigenartige herdförmige Erkrankung des Zentralnervensystems. Vorläufige Mitteilung. Z ges Neurol und Psychiat 1920; 57: 1–18.

3. Jakob A. Über eigenartige Erkrankungen des Zentralnervensystems mit bemerkenswerten anatomischen Befunde (spastische Pseudosklerose-Encephalomyelopathie mit disseminierten Degenerationsherden). Vorläufige Mitteilung. Deutsche Zeitschrift für Nervenheilkunde 1921; 70: 132–146.

4. Gajdusek DC, Zigas V. Degenerative disease of the central nervous system in New Guinea; the endemic occurrence of kuru in the native population. N Engl J Med 1957; 257(20): 974–978.

5. Matěj R, Rusina R, Koukolík F. 5 let činnosti Národní referenční laboratoře lidských prionových onemocnění při Oddělení patologie a molekulární medicíny FTNsP: naše zkušenosti a přehled literatury. Cesk Slov Neurol N 2007; 70/103(6): 637–642.

6. Will RG, Ironside JW, Zeidler M, Cousens SN, Estibeiro K, Alperovitch A et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996; 347(9006): 921–925.

7. Hewitt PE, Llewelyn CA, Mackenzie J, Will RG. Creutzfeldt-Jakob disease and blood transfusion: results of the UK Transfusion Medicine Epidemiological Review study. Vox Sang 2006; 91(3): 221–230.

8. Holada K, Simak J, Brown P, Vostal JG. Divergent Expression of Cellular Prion Protein (PrPC) on Blood Cells of Human and Non-human Primates. Transfusion 2007; 47(12): 2223–2232.

9. Aguzzi A, Baumann F, Bremer J. The prion’s elusive reason for being. Annu Rev Neurosci 2008; 31: 439–477.

10. Borchelt DR, Scott M, Taraboulos A, Stahl N, Prusiner SB. Scrapie and cellular prion proteins differ in their kinetics of synthesis and topology in cultured cells. J Cell Biol 1990; 110(3): 743–752.

11. Caughey B, Race RE, Ernst D, Buchmeier MJ, Chesebro B. Prion protein biosynthesis in scrapie-infected and uninfected neuroblastoma cells. J Virol 1989; 63(1): 175–181.

12. Pan KM, Baldwin M, Nguyen J, Gasset M, Serban A, Groth D et al. Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. Proc Natl Acad Sci U S A 1993; 90(23): 10962–10966.

13. Safar J, Roller PP, Gajdusek DC, Gibbs CJ jr. Conformational transitions, dissociation, and unfolding of scrapie amyloid (prion) protein. J Biol Chem 1993; 268(27): 20276–20284.

14. Govaerts C, Wille H, Prusiner SB, Cohen FE. Evidence for assembly of prions with left-handed beta--helices into trimers. Proc Natl Acad Sci U S A 2004; 101(22): 8342–8347.

15. Horiuchi M, Caughey B. Specific binding of normal prion protein to the scrapie form via a localized domain initiates its conversion to the protease-resistant state. EMBO J 1999; 18(12): 3193–3203.

16. Hobzová K, Janoušková O. Tkáňové kultury pro studium prionových chorob. Cesk Slov Neurol N 2010; 73(4): 379–386.

17. Collinge J, Gorham M, Hudson F, Kennedy A, Keogh G, Pal S et al. Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial. Lancet Neurol 2009; 8(4): 334–344.

18. Tsuboi Y, Doh-Ura K, Yamada T. Continuous intraventricular infusion of pentosan polysulfate: clinical trial against prion diseases. Neuropathology 2009; 29(5): 632–636.

19. Zerr I. Therapeutic trials in human transmissible spongiform encephalo-pathies: recent advances and problems to address. Infect Disord Drug Targets 2009; 9(1): 92–99.

20. Glierová H, Holada K. Úloha imunitního systému v prionových chorobách. Alergie 2006; 8(2): 143–148.

21. Sassa Y, Kataoka N, Inoshima Y, Ishiguro N. Anti-PrP antibodies detected at terminal stage of prion-affected mouse. Cell Immunol 2010; 263(2): 212–218.

22. Holada K. Prionové choroby a pokrok ve vývoji testu pro preklinickou detekci abnormálního prionového proteinu (PrPsc). Klin Mikrobiol Inf Lék 2005; 11(5): 151–160.

23. Safar J, Wille H, Itri V, Groth D, Serban H, Torchia M et al. Eight prion strains have PrP(Sc) molecules with different conformations. Nat Med 1998; 4(10): 1157–1165.

24. Safar JG, Geschwind MD, Deering C, Didorenko S, Sattavat M, Sanchez H et al. Diagnosis of human prion disease. Proc Natl Acad Sci U S A 2005; 102(9): 3501–3506.

25. Thackray AM, Hopkins L, Bujdoso R. Proteinase K-sensitive disease-associated ovine prion protein revealed by conformation-dependent immunoassay. Biochem J 2007; 401(2): 475–483.

26. Yakovleva O, Janiak A, McKenzie C, McShane L, Brown P, Cervenakova L. Effect of protease treatment on plasma infectivity in variant Creutzfeldt-Jakob disease mice. Transfusion 2004; 44(12): 1700–1705.

27. Holada K, Glierova H, Simak J, Vostal JG. Expression of cellular prion protein on platelets from patients with gray platelet or Hermansky-Pudlak syndrome and the protein‘s association with alpha-granules. Haematologica 2006; 91(8): 1126–1129.

28. Holada K, Simak J, Vostal JG. Transmission of BSE by blood transfusion. Lancet 2000; 356(9243): 1772.

29. Holada K, Simak J, Risitano AM, Maciejewski J, Young NS, Vostal JG. Activated platelets of pa­tients with paroxysmal nocturnal hemoglobinuria express cellular prion protein. Blood 2002; 100(1): 341–343.

30. Daude N, Lehmann S, Harris DA. Identification of intermediate steps in the conversion of a mutant prion protein to a scrapie-like form in cultured cells. J Biol Chem 1997; 272(17): 11604–11612.

31. Horiuchi M, Priola SA, Chabry J, Caughey B. Interactions between heterologous forms of prion protein: binding, inhibition of conversion, and species barriers. Proc Natl Acad Sci U S A 2000; 97(11): 5836–5841.

32. Pastrana MA, Sajnani G, Onisko B, Castilla J, Morales R, Soto C et al. Isolation and characterization of a proteinase K-sensitive PrPSc fraction. Biochemistry 2006; 45(51): 15710–15717.

33. Gambetti P, Dong Z, Yuan J, Xiao X, Zheng M, Alshekhlee A et al. A novel human disease with abnormal prion protein sensitive to protease. Ann Neurol 2008; 63(6): 697–708.

34. Jansen C, Parchi P, Jelles B, Gouw AA, Beunders G, van Spaendonk RM et al. The first case of fatal familial insomnia (FFI) in the Netherlands: a patient from Egyptian descent with concurrent four repeat tau deposits. Neuropathol Appl Neurobiol 2011; 37(5): 549–553.

35. Rodríguez-Martínez AB, Garrido JM, Zarranz JJ, Arteagoitia JM, de Pancorbo MM, Atarés B et al. A novel form of human disease with a protease-sensitive prion protein and heterozygosity methionine//valine at codon 129: Case report. BMC Neurol 2010; 10: 99.

36. Head MW, Knight R, Zeidler M, Yull H, Barlow A, Ironside JW. A case of protease sensitive prionopathy in a patient in the UK. Neuropathol Appl Neurobiol 2009; 35(6): 628–632.

37. Zou WQ, Puoti G, Xiao X, Yuan J, Qing L, Cali I et al. Variably protease-sensitive prionopathy: a new sporadic disease of the prion protein. Ann Neurol 2010; 68(2): 162–172.

38. Korth C, Stierli B, Streit P, Moser M, Schaller O, Fischer R et al. Prion (PrPSc)-specific epitope defined by a monoclonal antibody. Nature 1997; 390(6655): 74–77.

39. Spinner DS, Kascsak RB, Lafauci G, Meeker HC, Ye X, Flory MJ et al. CpG oligodeoxynucleotide-enhanced humoral immune response and production of antibodies to prion protein PrPSc in mice immunized with 139A scrapie-associated fibrils. J Leukoc Biol 2007; 81(6): 1374–1385.

40. Bainbridge J, Jones N, Walker B. Multiple antigenic peptides facilitate generation of anti-prion antibodies. Clin Exp Immunol 2004; 137(2): 298–304.

41. Büeler H, Fischer M, Lang Y, Bluethmann H, Lipp HP, DeArmond SJ et al. Normal development and beha­viour of mice lacking the neuronal cell-surface PrP protein. Nature 1992; 356(6370): 577–582.

42. Manson JC, Clarke AR, Hooper ML, Aitchison L, McConnell I, Hope J. 129/Ola mice carrying a null mutation in PrP that abolishes mRNA production are developmentally normal. Mol Neurobiol 1994; 8(2–3): 121–127.

43. Paramithiotis E, Pinard M, Lawton T, LaBoissiere S, Leathers VL, Zou WQ et al. A prion protein epitope selective for the pathologically misfolded conformation. Nat Med 2003; 9(7): 893–899.

44. Hedlin PD, Cashman NR, Li L, Gupta J, Babiuk LA, Potter A et al. Design and delivery of a cryptic PrP(C) epitope for induction of PrP(Sc)-specific antibody responses. Vaccine 2010; 28(4): 981–988.

45. Thackray AM, Madec JY, Wong E, Morgan-Warren R, Brown DR, Baron T et al. Detection of bovine spongiform encephalopathy, ovine scrapie prion-related protein (PrPSc) and normal PrPC by monoclonal antibodies raised to copper-refolded prion protein. Bio­chem J 2003; 370(1): 81–90.

46. Polymenidou M, Moos R, Scott M, Sigurdson C, Shi YZ, Yajima B et al. The POM monoclonals: a comprehensive set of antibodies to non-overlapping prion protein epitopes. PLoS One 2008; 3(12): e3872.

47. Jones M, Wight D, McLoughlin V, Norrby K, Ironside JW, Connolly JG et al. An antibody to the aggregated synthetic prion protein peptide (PrP106–126) selectively recognizes disease-associated prion protein (PrP) from human brain specimens. Brain Pathol 2009; 19(2): 293–302.

48. Horiuchi M, Karino A, Furuoka H, Ishiguro N, Kimura K, Shinagawa M. Generation of monoclonal antibody that distinguishes PrPSc from PrPC and neutralizes prion infectivity. Virology 2009; 394(2): 200–207.

49. Petsch B, Müller-Schiffmann A, Lehle A, Zirdum E, Prikulis I, Kuhn F et al. Biological effects and use of PrPSc- and PrP-specific antibodies generated by immunization with purified full-length native mouse prions. J Virol 2011; 85(9): 4538–4546.

50. Biasini E, Seegulam ME, Patti BN, Solforosi L, Medrano AZ, Christensen HM et al. Non-infectious aggregates of the prion protein react with several PrPSc-directed antibodies. J Neurochem 2008; 105(6): 2190–2204.

51. Moroncini G, Kanu N, Solforosi L, Abalos G, Telling GC, Head M et al. Motif-grafted antibodies containing the replicative interface of cellular PrP are specific for PrPSc. Proc Natl Acad Sci U S A 2004; 101(28): 10404–10409.

52. Williamson RA, Peretz D, Pinilla C, Ball H, Bastidas RB, Rozenshteyn R et al. Mapping the prion protein using recombinant antibodies. J Virol 1998; 72(11): 9413–9418.

53. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, Parren PW et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994; 266(5187): 1024–1027.

54. Solforosi L, Bellon A, Schaller M, Cruite JT, Abalos GC, Williamson RA. Toward molecular dissection of PrPC-PrPSc interactions. J Biol Chem 2007; 282(10): 7465–7471.

55. Curin Serbec V, Bresjanac M, Popovic M, Pretnar Hartman K, Galvani V, Rupreht R et al. Monoclonal antibody against a peptide of human prion protein discriminates between Creutzfeldt-Jacob‘s disease-affected and normal brain tissue. J Biol Chem 2004; 279(5): 3694–3698.

56. Kosmač M, Koren S, Giachin G, Stoilova T, Gennaro R, Legname G et al. Epitope mapping of a PrP(Sc)-specific monoclonal antibody: identification of a novel C-terminally truncated prion fragment. Mol Immunol 2011; 48(5): 746–750.

57. Zou WQ, Zheng J, Gray DM, Gambetti P, Chen SG. Antibody to DNA detects scrapie but not normal prion protein. Proc Natl Acad Sci U S A 2004; 101(5): 1380–1385.

58. Cordeiro Y, Machado F, Juliano L, Juliano MA, Brentani RR, Foguel D et al. DNA converts cellular prion protein into the beta-sheet conformation and inhibits prion peptide aggregation. J Biol Chem 2001; 276(52): 49400–49409.

59. Parchi P, Giese A, Capellari S, Brown P, Schulz-Schaeffer W, Windl O et al. Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol 1999; 46(2): 224–233.

60. Tayebi M, Jones DR, Taylor WA, Stileman BF, Chapman C, Zhao D et al. PrP(Sc)-specific antibodies with the ability to immunodetect prion oligomers. PLoS One 2011; 6(5): e19998.

61. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003; 300(5618): 486–489.

62. Choi YG, Kim JI, Jeon YC, Park SJ, Choi EK, Rubenstein R et al. Nonenzymatic glycation at the N terminus of pathogenic prion protein in transmissible spongiform encephalopathies. J Biol Chem 2004; 279(29): 30402–30409.

63. Panigaj M, Brouckova A, Glierova H, Dvorakova E, Simak J, Vostal JG et al. Underestimation of the expression of cellular prion protein on human red blood cells. Transfusion 2011; 51(5): 1012–1021.

64. Dvorakova E, Prouza M, Janouskova O, Panigaj M, Holada K. Development of monoclonal antibodies specific for glycated prion proteins. J Toxicol Environ Health A 2011; 74(22–24): 1469–1475.

65. Tschampa HJ, Zerr I, Urbach H. Radiological assessment of Creutzfeldt-Jakob disease. Eur Radiol 2007 May; 17(5): 1200–1211.

66. Sheardová K, Matěj R, Rektorová I. Hyperintenzivní léze reagující na steroidy u pacienta s Creutzfeldt‑Jakobovou nemocí. Cesk Slov Neurol N 2010; 73/106(1): 76–79.

67. Jirsova K, Krabcova I, Novakova J, Hnathova I, Koukolik F, Kubesova B et al. The assessment of pathogenic prions in the brains of eye tissue donors: 2-years experience in the Czech Republic. Cornea 2010; 29(9): 996–999.

68. Peretz D, Williamson RA, Kaneko K, Vergara J, Leclerc E, Schmitt-Ulms G et al. Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature 2001; 412(6848): 739–743.

69. White AR, Enever P, Tayebi M, Mushens R, Linehan J, Brandner S et al. Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 2003; 422(6927): 80–83.

70. Lefebvre-Roque M, Kremmer E, Gilch S, Zou WQ, Féraudet C, Gilles CM et al. Toxic effects of intracerebral PrP antibody administration during the course of BSE infection in mice. Prion 2007; 1(3): 198–206.

71. Wisniewski T, Goñi F. Immunomodulation for prion and prion-related diseases. Expert Rev Vaccines 2010; 9(12): 1441–1452.

Labels
Paediatric neurology Neurosurgery Neurology

Article was published in

Czech and Slovak Neurology and Neurosurgery

Issue 3

2012 Issue 3

Most read in this issue

This topic is also in:


Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account